Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer

Open access

Abstract

Tertiary lymphoid structures (TLS) are associated with favorable outcome in non-metastatic colorectal carcinoma (nmCRC), but the dynamics of TLS maturation and its association with effective anti-tumor immune surveillance in nmCRC are unclear. Here, we hypothesized that not only the number of TLS but also their composition harbors information on recurrence risk in nmCRC. In a comprehensive molecular, tissue, laboratory, and clinical analysis of 109 patients with stage II/III nmCRC, we assessed TLS numbers and degree of maturation in surgical specimens by multi-parameter immunofluorescence of follicular dendritic cell (FDC) and germinal center (GC) markers. TLS formed in most tumors and were significantly more prevalent in highly-microsatellite-instable (MSI-H) and/or BRAF-mutant nmCRC. We could distinguish three sequential TLS maturation stages which were characterized by increasing prevalence of FDCs and mature B-cells: [1] Early TLS, composed of dense lymphocytic aggregates without FDCs, [2] Primary follicle-like TLS, having FDCs but no GC reaction, and [3] Secondary follicle-like TLS, having an active GC reaction. A simple integrated TLS immunoscore reflecting these parameters identified a large subgroup of nmCRC patients with a very low risk of recurrence independently of clinical co-variables such as ECOG performance status, age, stage, and adjuvant chemotherapy. We conclude that (1) mismatch repair and BRAF mutation status are associated with the formation of TLS in nmCRC, (2) TLS formation in nmCRC follows sequential maturation steps, culminating in germinal center formation, and (3) this maturation process harbors important prognostic information on the risk of disease recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2017.1378844

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Tertiary lymphoid structures in stage II and III colorectal cancer. (A) The presence of TLS was analyzed in 109 CRC tissues by immunofluorescence and identified as dense B cell (CD20) aggregates. TLS near the invasive margin (white dashed line) of a CRC (T) and blood vessels (white stars). TLS with a central GC morphology (white arrowheads) or without (blue arrowheads) were counted. (B) The density of TLS in each patient was determined as the number of TLS per millimeter of tumor invasive front. (C) Comparison of TLS density in CRC patients with known MSI and BRAF mutation status. MSI-H and/or BRAF mutated CRCs (Mut-Hi, n = 15) were compared versus patients with wild type BRAF and MSS status (Mut-Lo, n = 94) by Wilcoxon rank-sum test.
Figure 1. Tertiary lymphoid structures in stage II and III colorectal cancer. (A) The presence of TLS was analyzed in 109 CRC tissues by immunofluorescence and identified as dense B cell (CD20) aggregates. TLS near the invasive margin (white dashed line) of a CRC (T) and blood vessels (white stars). TLS with a central GC morphology (white arrowheads) or without (blue arrowheads) were counted. (B) The density of TLS in each patient was determined as the number of TLS per millimeter of tumor invasive front. (C) Comparison of TLS density in CRC patients with known MSI and BRAF mutation status. MSI-H and/or BRAF mutated CRCs (Mut-Hi, n = 15) were compared versus patients with wild type BRAF and MSS status (Mut-Lo, n = 94) by Wilcoxon rank-sum test.CC BY-NC-ND · PubMed Central
Figure 2. Tertiary lymphoid structure maturation in stage II and III colorectal cancer. (A) The composition of TLS was analyzed by multi-parameter immunofluorescence using serial tissue sections of CRC. Two sets of antibodies were combined to visualize (1) the spatial organization of B cells (CD20), T cells (CD3), and CCL21 (top row), and (2) TLS maturation by the presence of FDCs (CD21), germinal center (GC) B cells (CD23), and CXCL13 (bottom row). (B) Different maturation stages were assessed by multiparameter immunofluorescence in CRC tissues. TLS in each maturation stage (E-TLS – dense lymphocytic clusters: CD21−CD23−, PFL-TLS – clusters with an FDC network: CD21+CD23−, SFL-TLS – clusters with active GC reaction: CD21+CD23+) were counted for each patient and expressed as the proportion of the total TLS count. The proportions of the three maturation stages were compared in patients with high (n = 84) and low (n = 25) TLS density (cut-off at the 25th percentile of TLS density distribution (i.e. Q1)) by a Wilcoxon rank-sum test. (C) The density of each TLS maturation stage was compared for patients with mutated BRAF and/or MSI-H status (Mut-hi, n = 15) versus patients with wild type BRAF and MSS status (Mut-lo, n = 94) by a two-tailed Mann-Whitney U test.
Figure 2. Tertiary lymphoid structure maturation in stage II and III colorectal cancer. (A) The composition of TLS was analyzed by multi-parameter immunofluorescence using serial tissue sections of CRC. Two sets of antibodies were combined to visualize (1) the spatial organization of B cells (CD20), T cells (CD3), and CCL21 (top row), and (2) TLS maturation by the presence of FDCs (CD21), germinal center (GC) B cells (CD23), and CXCL13 (bottom row). (B) Different maturation stages were assessed by multiparameter immunofluorescence in CRC tissues. TLS in each maturation stage (E-TLS – dense lymphocytic clusters: CD21−CD23−, PFL-TLS – clusters with an FDC network: CD21+CD23−, SFL-TLS – clusters with active GC reaction: CD21+CD23+) were counted for each patient and expressed as the proportion of the total TLS count. The proportions of the three maturation stages were compared in patients with high (n = 84) and low (n = 25) TLS density (cut-off at the 25th percentile of TLS density distribution (i.e. Q1)) by a Wilcoxon rank-sum test. (C) The density of each TLS maturation stage was compared for patients with mutated BRAF and/or MSI-H status (Mut-hi, n = 15) versus patients with wild type BRAF and MSS status (Mut-lo, n = 94) by a two-tailed Mann-Whitney U test.CC BY-NC-ND · PubMed Central
Figure 3. Tertiary lymphoid structure parameters and 3-year risk of colorectal cancer recurrence. Patients with low TLS counts (A), high proportions of E-TLS (B), and low proportions of PFL-TLS (C) showed a tendency towards numerically higher risks of recurrence. Patients with low SFL-TLS proportion (D) experienced a significantly higher risk of recurrence. Absolute risk estimates corresponding to these curves are reported in Table 2. Recurrence risks were estimated with competing risk analysis, treating death-from-any-cause as the competing event of interest. In the risk table, numbers in brackets represent the number of recurrences in the respective time interval. Abbreviations: Q1 – Cut-off at the 25th percentile of the variables' distribution (i.e. quartile 1), Q3 – Cut-off at the 75th percentile of the variable's distribution (i.e. quartile 3).
Figure 3. Tertiary lymphoid structure parameters and 3-year risk of colorectal cancer recurrence. Patients with low TLS counts (A), high proportions of E-TLS (B), and low proportions of PFL-TLS (C) showed a tendency towards numerically higher risks of recurrence. Patients with low SFL-TLS proportion (D) experienced a significantly higher risk of recurrence. Absolute risk estimates corresponding to these curves are reported in Table 2. Recurrence risks were estimated with competing risk analysis, treating death-from-any-cause as the competing event of interest. In the risk table, numbers in brackets represent the number of recurrences in the respective time interval. Abbreviations: Q1 – Cut-off at the 25th percentile of the variables' distribution (i.e. quartile 1), Q3 – Cut-off at the 75th percentile of the variable's distribution (i.e. quartile 3).CC BY-NC-ND · PubMed Central
Figure 4. Competing risk analysis of germinal-center-harboring TLS and 3-year risk of colorectal cancer recurrence. Cumulative incidences of recurrence were derived with competing risk analysis, accounting for death-from-any-cause as the competing risk of interest. Patients were dichotomized into two groups according to whether they had at least one TLS with an active GC reaction (n = 68) or not (n = 41). Risktables (“Number at risk”) report the number of patients in each group at risk of recurrence at the start of each time interval. The number of recurrences in each time interval (“Recurrences”) are reported in brackets.
Figure 4. Competing risk analysis of germinal-center-harboring TLS and 3-year risk of colorectal cancer recurrence. Cumulative incidences of recurrence were derived with competing risk analysis, accounting for death-from-any-cause as the competing risk of interest. Patients were dichotomized into two groups according to whether they had at least one TLS with an active GC reaction (n = 68) or not (n = 41). Risktables (“Number at risk”) report the number of patients in each group at risk of recurrence at the start of each time interval. The number of recurrences in each time interval (“Recurrences”) are reported in brackets.CC BY-NC-ND · PubMed Central
Figure 5. Path diagram of the structural equation model for estimating the relationship between TLS parameters, a latent TLS immune contexture variable, and colorectal cancer recurrence. Numbers to the right of the path represent path coefficients (or the log(hazard ratio) for the path from “immune_context” to “time2mets”)). Numbers in the right bottom of the square boxes represent the intercepts of the path coefficients. Numbers adjacent to the round error terms represent the errors of the measurements. Abbreviations: TLSmm – TLS count, E-TLS – Early TLS proportion, PFL-TLS – primary follicle like TLS proportion, SFL-TLS – secondary follicle like TLS proportion.
Figure 5. Path diagram of the structural equation model for estimating the relationship between TLS parameters, a latent TLS immune contexture variable, and colorectal cancer recurrence. Numbers to the right of the path represent path coefficients (or the log(hazard ratio) for the path from “immune_context” to “time2mets”)). Numbers in the right bottom of the square boxes represent the intercepts of the path coefficients. Numbers adjacent to the round error terms represent the errors of the measurements. Abbreviations: TLSmm – TLS count, E-TLS – Early TLS proportion, PFL-TLS – primary follicle like TLS proportion, SFL-TLS – secondary follicle like TLS proportion.CC BY-NC-ND · PubMed Central
Figure 6. Competing risk analysis of the Integrated TLS ImmunoScore (ITIS) and 3-year risk of colorectal cancer recurrence. Cumulative incidences of recurrence were derived with competing risk analysis, accounting for death-from-any-cause as the competing risk of interest. (A) The ITIS was categorized empirically into tertiles (T1, T2, and T3). (B) The ITIS was dichotomized into a binary variable at the cut-off suggested by the Classification And Regression Tree (CART) analysis at -12 points. Risktables (“Number at risk”) report the number of patients in each group at risk of recurrence at the start of each time interval. The number of recurrences in each time interval (“Recurrences”) are reported in brackets.
Figure 6. Competing risk analysis of the Integrated TLS ImmunoScore (ITIS) and 3-year risk of colorectal cancer recurrence. Cumulative incidences of recurrence were derived with competing risk analysis, accounting for death-from-any-cause as the competing risk of interest. (A) The ITIS was categorized empirically into tertiles (T1, T2, and T3). (B) The ITIS was dichotomized into a binary variable at the cut-off suggested by the Classification And Regression Tree (CART) analysis at -12 points. Risktables (“Number at risk”) report the number of patients in each group at risk of recurrence at the start of each time interval. The number of recurrences in each time interval (“Recurrences”) are reported in brackets.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Bendell JK TW, J Clin Oncol. 2016;34:15_suppl, 3502–3502

Cited by

See all 410

Metadata

Authors
Posch, F., Silina, K., Leibl, S., Mündlein, A., Moch, H., Siebenhüner, A., Samaras, P., Riedl, J., Stotz, M., Szkandera, J., Stöger, H., Pichler, M., Stupp, R., van den Broek, M., Schraml, P., Gerger, A., Petrausch, U., & Winder, T.
Affiliations
  • Medical University of Graz (AT)
  • Tumor Immunology Research Unit, Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, Zurich, Switzerland
  • University Hospital Zurich (CH)
  • Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, Feldkirch, Austria
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Gerger, Armin
Venue
OncoImmunology
Published
2017-12-18
Volume
7
Issue
2
Pages
e1378844-e1378844
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2754092421
Cited by
380
References
49
Citations by year
2026: 44 · 2025: 65 · 2024: 85 · 2023: 54 · 2022: 50 · 2021: 44 · 2020: 23 · 2019: 10 · 2018: 4 · 2017: 1
FWCI
4.58
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • OPUS (Augsburg University) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Swiss Cancer League (F-87701-31-01)
  • University of Zurich (K-84901-01-01)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
tertiary lymphoid structures, colorectal cancer, tumor recurrence, follicular dendritic cells, germinal center, microsatellite instability, BRAF mutation, DNA mismatch repair, prognostic factors, immune score

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. https://app.cochat.ai/papers/10.1080/2162402x.2017.1378844
The paper
Posch, F., Silina, K., Leibl, S., Mündlein, A., Moch, H., Siebenhüner, A., Samaras, P., Riedl, J., Stotz, M., Szkandera, J., Stöger, H., Pichler, M., Stupp, R., van den Broek, M., Schraml, P., Gerger, A., Petrausch, U., & Winder, T. (2018). Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1378844

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.